Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer (RNA-seq)

ABSTRACT: Our study examines the role of m6A RNA modification in regulating gene expression of transcripts promoting enzalutamide resistance in prostate cancer.

ORGANISM(S): Homo sapiens

PROVIDER: GSE249749 | GEO | 2024/05/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer (MeRIP-Seq)

Project description:Our study examines the role of m6A RNA modification in regulating gene expression of transcripts promoting enzalutamide resistance in prostate cancer.

2024-05-01 | GSE249748 | GEO

N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer

Project description:N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer

| PRJNA1050279 | ENA

Structure and Thermodynamics of N6-methyladenosine in RNA: a Spring-Loaded Base Modification

Project description:We determine m6A modification sites in GM12878 cells. Examination of m6A modification sites on the transcriptome of GM12878 cells, using a m6A-specific antibody.

2015-01-29 | E-GEOD-65380 | biostudies-arrayexpress

N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-05-01 | GSE249750 | GEO

N6-methyladenosine RNA modification drives a rapid shift to cisplatin resistance in bladder cancer by regulating SLC7A11 expression via YTHDF3 [RNA-seq]

Project description:Our study examines the role of m6A RNA modification in regulating gene expression of transcripts promoting cisplatin resistance in bladder cancer.

2023-11-08 | GSE231835 | GEO

N6-methyladenosine RNA modification drives a rapid shift to cisplatin resistance in bladder cancer by regulating SLC7A11 expression via YTHDF3 [RIP-seq]

Project description:Our study examines the role of m6A RNA modification in regulating gene expression of transcripts promoting cisplatin resistance in bladder cancer.

2023-11-08 | GSE231834 | GEO

N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer (RNA-seq)

Project description:N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer (RNA-seq)

| PRJNA1050281 | ENA

N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer (MeRIP-Seq)

Project description:N6-methyladenosine RNA modification is associated with enzalutamide resistance in prostate cancer (MeRIP-Seq)

| PRJNA1050277 | ENA

N6-methyladenosine Modulates Messenger RNA Translation Efficiency

Project description:N6-methyladenosine (m6A) is the most abundant internal messenger (mRNA) modification in mammalian mRNA. This modification is reversible and non-stoichiometric, which potentially adds an additional layer of variety and dynamic control of mRNA metabolism. The m6A-modified mRNA can be selectively recognized by the YTH family “reader” proteins. The preferential binding of m6A-containing mRNA by YTHDF2 is known to reduce the stability of the target transcripts; however, the exact effects of m6A on translation has yet to be elucidated. Here we show that another m6A reader protein, YTHDF1, promotes ribosome loading of its target transcripts. YTHDF1 forms a complex with translation initiation factors to elevate the translation efficiency of its bound mRNA. In a unified mechanism of translation control through m6A, the YTHDF2-mediated decay controls the lifetime of target transcripts; whereas, the YTHDF1-based translation promotion increases the translation efficiency to ensure effective protein production from relatively short-lived transcripts that are marked by m6A. PAR-CLIP and RIP was used to identify YTHDF1 binding sites followed by ribosome profling and RNA seq to assess the consequences of YTHDF1 siRNA knock-down

2015-06-09 | E-GEOD-63591 | biostudies-arrayexpress

N6-methyladenosine modification is essential for prostate cancer cells

Project description:N6-methyladenosine (m6A) modification of messenger RNAs (mRNAs) is a pivotal mechanism controlling mRNA fate in cells. RNA m6A modification is regulated by the functional balance between methyltransferases and demethylases. Here we demonstrated that FTO-IT1 enhancer RNA (eRNA), a long non-coding RNA (lncRNA) transcribed from the last intron of FTO gene is significantly upregulated in CRPC and aggressive tumors compared to primary tumors. FTO-IT1 knockout by CRISPR/Cas9 almost completely blocks growth and G1-S cell cycle transition of both androgen-sensitive and castration-resistant prostate cancer cells. Meanwhile, the mRNA m6A was dramatically increased in FTO-IT knockout PCa cells and we identified FTO-IT1 as a binding partner of FTO. From m6A-seq, we unexpectedly found hypermethylated m6A associated with upregulated levels of the mRNAs for p53 signaling pathway genes in 22Rv1 prostate cancer cells. Mechanistic study showed that FTO-IT1 recruits FTO to the P53 target mRNA to promote their m6A demethylation, which leads to their degradation.

2023-07-09 | GSE189465 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data